A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|8|658-664

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.8, 2015-08, pp. : 658-664

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 6, 2010-06 ,pp. : 1072-1078

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 1011-1019

John Wiley & Sons Inc

Access to resources Recommend Favorite

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 108-119

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of the peginterferon‐α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV‐co‐infected patients with the unfavourable non‐CC IL28B genotypes

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 21, Iss. 3, 2014-03 ,pp. : 178-188

John Wiley & Sons Inc

Access to resources Recommend Favorite

Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 5, 2015-05 ,pp. : 501-513

John Wiley & Sons Inc

Access to resources Recommend Favorite